Partnering with Pharma Companies: Why? How? And lessons learnt!

Many biotech companies aspire to “partner” with pharma companies but what does this really mean and why/how/when should they do so? What are the positives and what are the elephant traps? In this presentation we will use real life examples and experience to explore this very important topic and to provide participants with new perspectives for the future.

Edwin Moses

About Edwin Moses

Former CEO, Ablynx
Serial entrepreneur and value creator in European life science companies. As CEO built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over €500M in equity and debt financing. Oversaw multiple deal making at Ablynx which generated ~€0.5Bn in cash, >€10Bn in potential milestones plus royalties. Was responsible for developing the business plans and implementing them. Ran the sales process for each company generating values of £316M and €3.9Bn respectively. Expertise in high value service provision to the pharmaceutical industry and in drug discovery and development. Primarily focussed on high growth businesses and change management. 25 years of Board level experience in more than 10 companies, mostly as Chairman.

Our sponsors
Hyphen Projects uses cookies to remember certain preferences and align jobs interests.
By continuing to use this site, you consent to our use of cookies. For more information, read: